Thymosin Alpha-1: Safety Profile & Research Summary
$53.55 · Lot COA published · Free BAC water + free U.S. shipping · Same-day dispatch before 2 PM ET · FOR RESEARCH USE ONLY
Buy Thy Alpha 1 Peptide 10mg (Zadaxin)24 PubMed CitationsExpert ReviewedLast Reviewed: February 2026
Clinical Trials
✅ Thymosin Alpha 1 is one of the most clinically studied peptides in existence, with 10+ completed clinical trials and approval in 30+ countries as Zadaxin (thymalfasin).
| Trial | Phase | n= | Indication | Key Result | Status |
|---|---|---|---|---|---|
| ETASS | Phase 3 | 361 | Severe sepsis | Mortality endpoint | — |
| TESTS | Phase 3 | 1,106 | Sepsis | Mortality endpoint | — |
| US HBV | Phase 3 | 99 | Hepatitis B | Virologic-response endpoint | — |
| Japan HBV | RCT | 316 | Hepatitis B | ALT-normalization endpoint | — |
| HCV Triple | RCT | 552 | Hepatitis C | Sustained-virologic-response endpoint | — |
| Wuhan COVID | Retro | 76 | Severe COVID-19 | Immune-marker endpoints | — |
| Melanoma | Phase 2 | 488 | Metastatic melanoma | Overall-survival endpoint | — |
| NIBIT-M4 | F/U | 95 | Melanoma + Ipilimumab | Overall-survival endpoint | — |
| GASTO-1043 | Phase 2 | 196 | NSCLC + chemoRT | Pneumonitis endpoint | — |
| H1N1 Vaccine | Pilot | 122 | Hemodialysis study subjects | Seroconversion endpoint | — |
Preclinical Animal Data (Selected)
- Lung Cancer (LLC/H460): 0.25 mg/kg × 11 days — 40.5% tumor volume inhibition (LLC), 21.9% inhibition (H460). Promoted CD4+/CD8+ T cell infiltration. [22]
- Melanoma (B16F10): Monotherapy reduced lung metastases by 32% (P<0.05); tumor growth decreased 34–46% (P=0.001–0.015). [5]
- Lung Adenoma Prevention: 0.4 mg/kg daily — reduced adenoma multiplicity by ~45% at 2.5 months.
- Leukemia/Carcinoma Combo: Tα1 (200 µg/kg) + IL-2/IFN + cyclophosphamide: tumor-regression endpoints reported in FLC and 3LL models. [23]
- Sepsis (CLP): Tα1 + dexamethasone achieved highest survival rate; reversed DC depletion.
- Immunosuppression: 100–1,000× more active than thymosin fraction 5 in restoring immunity in 5-FU models.
- Aging: Restored antibody and T-cell responses in aged mice (23–24 months) to levels comparable to young animals. [24]
- Arthritis (CIA): 0.25–1 mg/kg reduced paw volume, weight, and arthritic scores.
Reported Tolerability Profile
Tα1 is consistently reported as well-tolerated across 2,000+ clinical subjects. [1]
- Common: Local reactions (most frequent)
- Rare: Fever, fatigue, muscle aches, nausea (usually when combined with IFN)
- Hepatic: Transient ALT flares in HBV research application (often a sign of experimental effect)
- Serious (rare): Fatal immune hemolytic anemia and engraftment failure in HSCT recipients
- Preclinical: Single doses up to 20 mg/kg and 13-week repeated doses up to 6 mg/kg/day showed no observed toxicity
Handling: Handle with standard laboratory PPE. Consult the SDS.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
In Vitro / Preclinical Disclaimer: The research findings described above were observed in laboratory (in vitro) and/or animal model studies. These results may not translate to human outcomes. No claims are made regarding human therapeutic applications.
Educational Use Only: This content summarises published laboratory and clinical literature for research reference only. It is not medical advice.
Editorial Research Note
“Clinical Trials ✅ Thymosin Alpha 1 is one of the most clinically studied peptides in existence, with 10+ completed clinical trials and approval in 30+ countries as Zadaxin (thymalfasin).”
References
- Dominari A, Hathaway III D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol, 9(5), 67-78, 2020.
- Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: Isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA, 74(2), 725-729, 1977.
- Li J, Liu CH, Wang FS. Thymosin alpha 1: biological activities, applications and genetic engineering production. Peptides, 31(11), 2151-2158, 2010.
- Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood, 103(11), 4232-4239, 2004.
- King R, Tuthill C. Vitamins and Hormones, 102, 151-178, 2016.
- Pica F, Chimenti MS, Gaziano R, et al. Clin Exp Immunol, 186(1), 39-45, 2016.
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2025.
- Elizondo-Riojas MA, Chamow SM, Tuthill CW, et al. Biochem Biophys Res Commun, 416(3-4), 356-61, 2011.
- Billich A. Thymosin alpha1. SciClone Pharmaceuticals. Curr Opin Investig Drugs, 3(5), 698-707, 2002.
- Garaci E. Thymosin alpha1: a historical overview. Ann N Y Acad Sci, 1112, 14-20, 2007.
- Tao N, Xu X, Ying Y, et al. Molecules, 28(8), 3539, 2023.
- Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood, 108(7), 2265-74, 2006.
- Serafino A, Pica F, Andreola F, et al. J Innate Immun, 6(1), 72-88, 2014.
- Maio M, Mackiewicz A, Testori A, et al. J Clin Oncol, 28(10), 1780-1787, 2010.
- Costantini C, Bellet MM, Pariano M, et al. Front Oncol, 9, 873, 2019.
- Wu J, Zhou L, Liu J, et al. Critical Care, 17(1), R8, 2013.
- Liu Y, Pan Y, Hu Z, et al. Clin Infect Dis, 71(16), 2150-2157, 2020.
- Matteucci C, Grelli S, Balestrieri E, et al. Future Microbiol, 12, 141-155, 2017.
- Carraro G, Naso A, Montomoli E, et al. Vaccine, 30(6), 1170-1180, 2012.
- Romani L, Oikonomou V, Moretti S, et al. Nat Med, 23(5), 590-600, 2017.
- Pica F, Chimenti MS, Gaziano R, et al. Serum thymosin alpha 1 levels in chronic inflammatory autoimmune diseases. Clin Exp Immunol, 186(1), 39-45, 2016.
- Peng R, Xu C, Zheng H, et al. Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo. ACS Omega, 5(18), 10374-10381, 2020.
- Garaci E, Mastino A, Pica F, Favalli C. Cancer Immunol Immunother, 32(3), 154-160, 1990.
- Simonova MA, Ivanov I, Shoshina NS, et al. Aging and Thymosin Alpha-1. Int J Mol Sci, 26(23), 11470, 2025.
Related Research Questions
Related research
Browse all research guides in the Peptide Research Library →Want the complete research review?
Buy Thy Alpha 1 Peptide 10mg (Zadaxin)→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.